Compare Abbott Laboratories (ABT) vs Morgan Stanley (MS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Morgan Stanley — how do they compare? Abbott Laboratories trades at $95.36 (market cap $166.94B), while Morgan Stanley trades at $218.55 (market cap $350.22B). The key difference: Morgan Stanley is far larger — about 2.1× Abbott Laboratories's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | MS | |
|---|---|---|
Market Cap | $166.94B | $350.22B |
Sector | Health | Financials |
52-Week High | $136.62 | $227.19 |
52-Week Low | $82.57 | $139.09 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Morgan Stanley (MS) trades at $222.10, up 3.82% today, near its consensus price target of $225.80. The stock shows strong fundamental momentum with three consecutive quarterly earnings beats and robust revenue growth, reaching $66.0B in 2025. Technical indicators are bullish, with the current price above key support levels. Recent news highlights the firm's role in leading Anthropic's IPO and expanding AI integration in wealth management.
The outlook remains positive given earnings outperformance and analyst consensus, though risks include volatile cash flows and high debt levels. Upside potential exists if the company maintains its growth trajectory and executes on strategic initiatives like the Anthropic IPO. Investors should monitor interest rate sensitivity and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
